Sort
15,273 grants matching “antimicrobial resistance”
Site-directed spin labeling of ArnT
$219,713Candice S Klug · Medical College Of Wisconsin · R01 · FY2006 · AI
Deriving P. acnes Bacteriophages from Skin for Acne Therapy
$219,713Robert L Modlin · University Of California Los Angeles · R21 · FY2011 · AR
Development of a Genotype-linked Antibiotic Resistance Platform for Real Time Pathogen Risk Classification and Epidemiology
$219,655Patricia Chan · Maverix Biomics, Inc. · R41 · FY2016 · AI
Genetic Analysis of Beneficial Bacterial Colonization
$219,597Mark J Mandel · University Of Wisconsin-Madison · R35 · FY2021 · GM
Development of Streptothricin Class Antimicrobials as Novel Therapeutics
$219,329Roman Manetsch · Northeastern University · R21 · FY2019 · AI
Sodium bioenergetics in Yersinia pestis
$219,300Claudia C Hase · Oregon State University · R21 · FY2010 · AI
Evaluating the Bilayer-Couple Model of Outer Membrane Vesicle Biogenesis Using Novel Asymmetric Membrane Templates
$219,300Jeffrey Schertzer · State University Of Ny,Binghamton · R21 · FY2016 · AI
Administrative Core
$219,267Michael S. Gilmore · Massachusetts Eye And Ear Infirmary · P01 · FY2022 · AI
An Integrated Catheter Dressing for Early Detection of Catheter-related Bloodstream Infections
$219,251Hatice Ceylan Koydemir · Texas A&M University · R21 · FY2024 · GM
VACCINE AND TREATMENT EVALUATION UNIT: Phase 4 Tuberculosis Therapeutics Trial
$219,240Daniel Hoft · Saint Louis University · N01 · FY2017 · AI
Structure,Function, and Inhibition of Beta-lactamases
$219,142Northwestern University · R01 · FY2001 · GM
Specific anti-TB compounds from uncultured bacteria
$219,069Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R43 · FY2015 · AI
Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis
$219,058Robert B Abramovitch · Michigan State University · R21 · FY2017 · AI
INTERDISCIPLINARY PROGRAM IN BACTERIAL PATHOGENESIS
$219,057Ferric C Fang · University Of Washington · T32 · FY2019 · AI
Markers predicting response to therapy for KPC-producing Klebsiella pneumoniae
$219,042Yohei Doi · University Of Pittsburgh At Pittsburgh · R21 · FY2013 · AI
A Dual-drug Delivery to Inhibit Causes of Periodontal Diseases
$219,019Rajiv Kumar Satsangi · Rann Research Corporation · R43 · FY2012 · DE
NhaP-type cation-proton antiporters in Vibrio cholerae and Yersinia pestis
$219,000Claudia C Hase · Oregon State University · R21 · FY2014 · AI
Augmenting innate immunity to combat nasal carriage of Staphylococcus aureus
$219,000Alexander M Cole · University Of Central Florida · R21 · FY2017 · AI
Genomic diversity of Candida bloodstream infections
$219,000M. Hong Thi Nguyen · University Of Pittsburgh At Pittsburgh · R21 · FY2022 · AI
Project 1: Elucidating the Mechanisms of S. aureus Motility in Bone and Developing Interventions
$218,934Hani A Awad · University Of Rochester · P50 · FY2019 · AR
Staphylococcus aureus and Pseudomonas aeruginosa interactions in wound pathogenesis
$218,871Alexander R Horswill · University Of Colorado Denver · R21 · FY2023 · AI
Mechanism and Spread of Qnr-Mediated Resistance
$218,751Massachusetts General Hospital · R01 · FY2005 · AI
Identification of potentiators of antimicrobial activity against multidrug-resistant Burkholderia cepacia complex infections in cystic fibrosis
$218,750Thea Brennan-Krohn · Beth Israel Deaconess Medical Center · R21 · FY2022 · AI
TASK A29: In vitro testing for Antimicrobial Resistant-related antibacterial activity
$218,716Thomas Patterson · University Of Texas Hlth Science Center · N01 · FY2017 · AI
Task A36: In vitro testing for antimicrobial resistant-related antibacterial activity
$218,715Thomas Patterson · University Of Texas Hlth Science Center · N01 · FY2018 · AI